Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-01-24

FDA Approved: ROCKLATAN — Supplemental Application (Alcon Laboratories, Inc.)

View source ↗

Summary

FDA approved a supplemental application for ROCKLATAN (netarsudil and latanoprost ophthalmic solution) from Alcon Laboratories, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ROCKLATAN (Netarsudil and latanoprost ophthalmic solution, 0.02%/0.005%)

Snippet

SUPPL AP for ROCKLATAN (NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION, 0.02%/0.005%)